CTOs on the Move


 
Ivenix, Inc. is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company is headquartered in Amesbury, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ivenix.com
  • 21 Water St
    Amesbury, MA USA 01913
  • Phone: 978.792.5000

Executives

Name Title Contact Details

Funding

Ivenix raised $42M on 09/01/2015

Similar Companies

FONEMED

Fonemed provides virtual nurse triage and software solutions to increase access to quality healthcare and control costs. Fonemed was founded in 1996 by a group of physicians, philanthropists and businesspeople who recognized the need for improved healthcare worldwide and saw telephone-based triage as the premier method to provide that care.

Blue Ridge Medical Imaging

Blue Ridge Medical Imaging is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Howard County General Hospital

Howard County General Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Howard County General Hospital is based in Columbia, MD. You can find more information on Howard County General Hospital at www.hcgh.org

Technology Commercialization Group

Technology Commercialization Group is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.